KFDA approved Novartis' Lucentis, a vision recovery therapy.

The KFDA has approved Lucentis (ranibizumab) injectable drug filed by Novartis Korea for the treatment of wet age-related macular degeneration (AMD), which will be the first therapeutic drug ever sold in Korea.

AMD is a chronic condition of the eye that causes central vision loss. It affects our central vision, which is the center area of what we see. In fact, most of the things we do everyd...